Interdepartmental Division of Critical Care Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Departments of Critical Care and Medicine, Unity Health Toronto - St. Michael's Hospital, Toronto, Ontario, Canada.
Thorax. 2022 Aug;77(8):752-761. doi: 10.1136/thoraxjnl-2021-216993. Epub 2021 Oct 29.
Extubation to non-invasive ventilation (NIV) has been investigated as a strategy to wean critically ill adults from invasive ventilation and reduce ventilator-related complications.
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, proceedings of four conferences and bibliographies (to June 2020) for randomised and quasi-randomised trials that compared extubation with immediate application of NIV to continued invasive weaning in intubated adults and reported mortality (primary outcome) or other outcomes. Two reviewers independently screened citations, assessed trial quality and abstracted data.
We identified 28 trials, of moderate-to-good quality, involving 2066 patients, 44.6% with chronic obstructive pulmonary disease (COPD). Non-invasive weaning significantly reduced mortality (risk ratio (RR) 0.57, 95% CI 0.44 to 0.74; high quality), weaning failures (RR 0.59, 95% CI 0.43 to 0.81; high quality), pneumonia (RR 0.30, 95% CI 0.22 to 0.41; high quality), intensive care unit (ICU) (mean difference (MD) -4.62 days, 95% CI -5.91 to -3.34) and hospital stay (MD -6.29 days, 95% CI -8.90 to -3.68). Non-invasive weaning also significantly reduced the total duration of ventilation, duration of invasive ventilation and duration of ventilation related to weaning (MD -0.57, 95% CI -1.08 to -0.07) and tracheostomy rate. Mortality, pneumonia, reintubation and ICU stay were significantly lower in trials enrolling COPD (vs mixed) populations.
Non-invasive weaning significantly reduced mortality, pneumonia and the duration of ventilation related to weaning, particularly in patients with COPD. Beneficial effects are less clear (or more careful patient selection is required) in non-COPD patients.
CRD42020201402.
为了使危重症患者脱离有创通气并减少与通气相关的并发症,已经研究了将气管插管患者拔管后立即应用无创通气(NIV)的策略。
我们检索了 MEDLINE、EMBASE、Cochrane 对照试验中心注册库、4 次会议的会议记录和参考文献(截至 2020 年 6 月),以确定比较拔管后立即应用 NIV 与继续有创撤机的随机和半随机试验,这些试验报告了死亡率(主要结局)或其他结局。两名审查员独立筛选引文、评估试验质量并提取数据。
我们确定了 28 项试验,这些试验质量为中等到良好,涉及 2066 例患者,其中 44.6%为慢性阻塞性肺疾病(COPD)患者。与继续有创撤机相比,无创撤机显著降低了死亡率(风险比(RR)0.57,95%置信区间(CI)0.44 至 0.74;高质量)、撤机失败率(RR 0.59,95%CI 0.43 至 0.81;高质量)、肺炎(RR 0.30,95%CI 0.22 至 0.41;高质量)、重症监护病房(ICU)入住率(平均差值(MD)-4.62 天,95%CI -5.91 至 -3.34)和住院时间(MD -6.29 天,95%CI -8.90 至 -3.68)。无创撤机还显著降低了总通气时间、有创通气时间和与撤机相关的通气时间(MD -0.57,95%CI -1.08 至 -0.07)以及气管切开术率。在 COPD(与混合)人群中进行的试验中,死亡率、肺炎、与撤机相关的肺炎和通气时间显著降低。在非 COPD 患者中,有益效果不太明显(或需要更仔细的患者选择)。
与继续有创撤机相比,无创撤机显著降低了死亡率、肺炎和与撤机相关的通气时间,特别是在 COPD 患者中。在非 COPD 患者中,有益效果不太明显(或需要更仔细的患者选择)。
PROSPERO 注册号:CRD42020201402。